Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Interim Analysis Expected End of 2Q 2025 BETHESDA, MD, Mar 14, 2025 – (ACN Newswire) – Gain Therapeutics, Inc. (Nasdaq: GANX) […]
Interim Analysis Expected End of 2Q 2025 BETHESDA, MD, Mar 14, 2025 – (ACN Newswire) – Gain Therapeutics, Inc. (Nasdaq: GANX) […]